{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:26:06Z","timestamp":1755793566006,"version":"3.44.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010792","name":"Tungs' Taichung MetroHarbor Hospital","doi-asserted-by":"publisher","award":["R1110049","R1130018","R1130019","R1120020","TTMHH-R1110002"],"award-info":[{"award-number":["R1110049","R1130018","R1130019","R1120020","TTMHH-R1110002"]}],"id":[{"id":"10.13039\/100010792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-860-001-MY3","109-2314-B-860-001"],"award-info":[{"award-number":["110-2314-B-860-001-MY3","109-2314-B-860-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Biochemistry and Biophysics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.abb.2025.110549","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T07:54:04Z","timestamp":1752566044000},"page":"110549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bim and Mcl-1 coordinate NVP-BEZ235-induced renal cell carcinoma cell apoptosis"],"prefix":"10.1016","volume":"772","author":[{"given":"Yen-Chuan","family":"Ou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ri","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Lan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsiang","family":"Kuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-6737","authenticated-orcid":false,"given":"Chun-Jung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.abb.2025.110549_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.abb.2025.110549_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrurol.2016.260","article-title":"Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics","volume":"14","author":"Linehan","year":"2017","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.abb.2025.110549_bib3","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1038\/s41598-021-86218-x","article-title":"Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC)","volume":"11","author":"Ar\u00e9valo","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.abb.2025.110549_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3892\/etm.2021.9972","article-title":"PI3K\/AKT\/mTORsignalling pathway involvement in renal cell carcinoma pathogenesis","volume":"21","author":"Miricescu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.abb.2025.110549_bib5","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1158\/0008-5472.CAN-20-3979","article-title":"mTOR activation initiates renal cell carcinoma development by coordinating ERK and p38MAPK","volume":"81","author":"Wu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.abb.2025.110549_bib6","doi-asserted-by":"crossref","first-page":"6749","DOI":"10.1158\/1078-0432.CCR-21-0972","article-title":"Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade","volume":"27","author":"Terry","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2025.110549_bib7","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9261","article-title":"Prognostic significance of PI3K\/AKT\/mTOR signaling pathway members in clear cell renal cell carcinoma","volume":"8","author":"Fan","year":"2020","journal-title":"PeerJ"},{"key":"10.1016\/j.abb.2025.110549_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737140.2014.864562","article-title":"Temsirolimus for advanced renal cell carcinoma","volume":"14","author":"Bergmann","year":"2014","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.abb.2025.110549_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.21037\/apm-20-2465","article-title":"Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma","volume":"10","author":"Ren","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.abb.2025.110549_bib10","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1002\/cam4.1748","article-title":"Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of akt\/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways","volume":"7","author":"Son","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.abb.2025.110549_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","article-title":"A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma","volume":"21","author":"Carlo","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.abb.2025.110549_bib12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bju.13415","article-title":"Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma","volume":"118","author":"Seront","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.abb.2025.110549_bib13","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"Cho","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.abb.2025.110549_bib14","article-title":"NVP-BEZ235 inhibits renal cell carcinoma by targeting TAK1 and PI3K\/Akt\/mTOR pathways","volume":"12","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.abb.2025.110549_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cbf.2917","article-title":"Inhibition of autophagy enhances apoptosis induced by the PI3K\/AKT\/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells","volume":"31","author":"Li","year":"2013","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.abb.2025.110549_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1476-4598-10-90","article-title":"Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib","volume":"10","author":"Roulin","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.abb.2025.110549_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104413","article-title":"mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma","volume":"9","author":"Bailey","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.abb.2025.110549_bib18","doi-asserted-by":"crossref","first-page":"19147","DOI":"10.18632\/aging.103723","article-title":"BRD4 inhibition sensitizes renal cell carcinoma cells to the PI3K\/mTOR dual inhibitor VS-5584","volume":"12","author":"Xu","year":"2020","journal-title":"Aging. (Albany NY)"},{"key":"10.1016\/j.abb.2025.110549_bib19","doi-asserted-by":"crossref","DOI":"10.4238\/gmr16039278","article-title":"Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues","volume":"16","author":"Xia","year":"2017","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.abb.2025.110549_bib20","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1038\/sj.onc.1210510","article-title":"Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance","volume":"26","author":"Zantl","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.abb.2025.110549_bib21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3892\/ol.2020.12189","article-title":"Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell","volume":"20","author":"Zhu","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.abb.2025.110549_bib22","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.3390\/ijms20112792","article-title":"Fibronectin promotes cell growth and migration in human renal cell carcinoma cells","volume":"20","author":"Ou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.abb.2025.110549_bib23","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.3390\/ijms21124219","article-title":"Aspirin induced glioma apoptosis through Noxa upregulation","volume":"21","author":"Chang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.abb.2025.110549_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41419-021-03451-y","article-title":"Molecular imaging of the kinetics of hyperactivated ERK1\/2-mediated autophagy during acquirement of chemoresistance","volume":"12","author":"Bishnu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.abb.2025.110549_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111415","article-title":"MEK inhibitor trametinib combined with PI3K\/mTOR inhibitor BEZ-235 as an effective strategy against NSCLC through impairment of glucose metabolism","volume":"124","author":"Liu","year":"2024","journal-title":"Cell. Signal."},{"key":"10.1016\/j.abb.2025.110549_bib26","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1002\/cncr.26656","article-title":"Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.abb.2025.110549_bib27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.7150\/jca.29192","article-title":"Dual-inhibition of mTOR and Bcl-2 enhances the anti-tumor effect of everolimus against renal cell carcinoma in Vitro and in Vivo","volume":"10","author":"Nayman","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.abb.2025.110549_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lfs.2014.02.002","article-title":"Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis","volume":"100","author":"Ou","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.abb.2025.110549_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2018.05.142","article-title":"Aspirin restores ABT-737-mediated apoptosis in human renal carcinoma cells","volume":"502","author":"Ou","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.abb.2025.110549_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11010-016-2938-0","article-title":"YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells","volume":"429","author":"Woo","year":"2017","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.abb.2025.110549_bib31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CMAR.S265788","article-title":"Synergistic effects of TW-37 and ABT-263 on renal cell carcinoma cells","volume":"13","author":"Yu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.abb.2025.110549_bib32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/carcin\/bgy135","article-title":"STAT3- and GSK3\u03b2-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma","volume":"40","author":"Maji","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.abb.2025.110549_bib33","article-title":"HSPB1 facilitates ERK-mediated phosphorylation and degradation of BIM to attenuate endoplasmic reticulum stress-induced apoptosis","volume":"31","author":"Kennedy","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.abb.2025.110549_bib34","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1038\/s41388-019-0865-8","article-title":"SOX7 regulates MAPK\/ERK-BIM mediated apoptosis in cancer cells","volume":"38","author":"Sun","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.abb.2025.110549_bib35","article-title":"Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression, cell","volume":"5","author":"Woo","year":"2014","journal-title":"Death Dis."},{"key":"10.1016\/j.abb.2025.110549_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10495-022-01718-z","article-title":"Ambra1 regulates apoptosis and chemosensitivity in breast cancer cells through the Akt-FoxO1-Bim pathway","volume":"27","author":"Sun","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.abb.2025.110549_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095588","article-title":"Curcumin significantly enhances dual PI3K\/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability","volume":"9","author":"Seo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.abb.2025.110549_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-016-0565-8","article-title":"Choosing the right cell line for renal cell cancer research","volume":"15","author":"Brodaczewska","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.abb.2025.110549_bib39","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2014.03.001","article-title":"PI3K\/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced","volume":"348","author":"Jebahi","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.abb.2025.110549_bib40","first-page":"125","article-title":"XIAP underlies apoptosis resistance of renal cell carcinoma cells","volume":"17","author":"Yang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.abb.2025.110549_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging. (Albany NY)"},{"key":"10.1016\/j.abb.2025.110549_bib42","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170169","article-title":"Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclaxin lymphoid malignancies","volume":"133","author":"Chong","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.abb.2025.110549_bib43","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.4161\/cc.6.18.4728","article-title":"Bimand the pro-survival Bcl-2 proteins: opposites attract, ERK repels","volume":"6","author":"Ewings","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.abb.2025.110549_bib44","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745235","article-title":"Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance","volume":"19","author":"Kale","year":"2018","journal-title":"EMBO Rep."},{"key":"10.1016\/j.abb.2025.110549_bib45","article-title":"Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells, evid. Based. Complement","volume":"2013","author":"Ou","year":"2013","journal-title":"Alternat. Med."},{"key":"10.1016\/j.abb.2025.110549_bib46","first-page":"841","article-title":"Bcl-XL and Mcl-1 upregulation by calreticulin promotes apoptosis resistance of fibroblast-like synoviocytes via activation of PI3K\/Akt and STAT3 pathways in rheumatoid arthritis","volume":"36","author":"Jiao","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.abb.2025.110549_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/15384047.2018.1504718","article-title":"Combined inhibition of the PI3K\/mTOR\/MEK pathway induces Bim\/Mcl-1-regulated apoptosis in pancreatic cancer cells","volume":"20","author":"Burmi","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.abb.2025.110549_bib48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.freeradbiomed.2014.07.039","article-title":"FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells, free","volume":"76","author":"Shukla","year":"2014","journal-title":"Radic. Biol. Med."},{"key":"10.1016\/j.abb.2025.110549_bib49","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.18632\/oncotarget.13987","article-title":"Dual inhibition of the PI3K\/AKT\/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications","volume":"8","author":"Fourneaux","year":"2017","journal-title":"Oncotarget"}],"container-title":["Archives of Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986125002620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003986125002620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:21:59Z","timestamp":1755235319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986125002620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":49,"alternative-id":["S0003986125002620"],"URL":"https:\/\/doi.org\/10.1016\/j.abb.2025.110549","relation":{},"ISSN":["0003-9861"],"issn-type":[{"type":"print","value":"0003-9861"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bim and Mcl-1 coordinate NVP-BEZ235-induced renal cell carcinoma cell apoptosis","name":"articletitle","label":"Article Title"},{"value":"Archives of Biochemistry and Biophysics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abb.2025.110549","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110549"}}